Mergers & Acquisitions - Global

Filter

Current filters:

Global

Popular Filters

Oxford BioMedica enters LentiVector collaboration with Novartis

Oxford BioMedica enters LentiVector collaboration with Novartis

10-10-2014

UK-based Oxford BioMedica says that it has signed further contracts with Swiss pharma giant Novartis,…

GlobalLentiVectorLicensingMergers & AcquisitionsNovartisOncologyOxford BioMedicaPharmaceutical

Mood lifts for Medtech in first half of 2014, while Pharma sector faces new struggles

Mood lifts for Medtech in first half of 2014, while Pharma sector faces new struggles

20-08-2014

An M&A frenzy that accounted for nearly $90 billion of equity set the pace for the first half of 2014…

FinancialGlobalJonathan GardnerMergers & AcquisitionsPharmaceutical

EXPERT VIEW: Pfizer and AstraZeneca, a marriage not to be – yet?

EXPERT VIEW: Pfizer and AstraZeneca, a marriage not to be – yet?

19-08-2014

Mergers and acquisitions may excite the markets and shareholders on both sides but their record of success…

GlobalInterviewsMergers & AcquisitionsPharmaceutical

$260.2 billion-worth of deals in the global PMB industry in first-half 2014

$260.2 billion-worth of deals in the global PMB industry in first-half 2014

12-08-2014

Global pharma, medical and biotechnology (PMB) M&A activity during the first half of 2014 hit the highest…

Business FinanceGlobalMergers & AcquisitionsPharmaceutical

Pharma more optimistic about future despite upcoming industry consolidation

Pharma more optimistic about future despite upcoming industry consolidation

13-06-2014

More than 69% of senior players within the pan-world pharma industry expect to see a year-on-year increase…

FinancialGlobalMergers & AcquisitionsPharmaceutical

In Focus: Strong drivers will keep the pharma M&A pipeline bubbling

In Focus: Strong drivers will keep the pharma M&A pipeline bubbling

28-05-2014

The record start to 2014’s pharma M&A has been a welcome boost to a deal market that had been in the…

CancerGlobalInterviewsMergers & AcquisitionsPfizerPharmaceuticalPharmaceutical industryPharmaceutical sciences

Pharmaceutical and life sciences deal volume up 53% in 1st-qtr, sets stage for heightened activity in 2014

21-05-2014

Pharmaceutical and life sciences (PLS) merger and acquisition (M&A) volume increased 53.1% in the first…

GlobalMergers & AcquisitionsPharmaceutical

Sustainability of sky-high M&A valuations will be the biggest question for 2014, says new report

12-03-2014

The cautious optimism of 2012 turned into a fully fledged biotech boom in 2013, marked by surging company…

BiotechnologyGlobalMergers & AcquisitionsPharmaceutical

Big pharma's need to tap M&A for growth will persist in 2014, while dealmaking landscape becomes more competitive, says EY

13-01-2014

Big pharma stayed on the sidelines in the 2013 mergers and acquisitions market despite a continuing need…

GlobalMergers & AcquisitionsPharmaceutical

Pharma M&A deals in 2013 down, but values marginally higher

Pharma M&A deals in 2013 down, but values marginally higher

13-01-2014

Merger and acquisition activity in the pharmaceutical, biotechnology and generic drugs sectors continued…

BiotechnologyGlobalMergers & AcquisitionsPharmaceutical

Clinigen acquires oncology support therapy Cardioxane from Novartis

26-03-2013

UK-based Clinigen Group (LSE: CLIN) says it has acquired (AIM: CLIN) the oncology support therapy Cardioxane…

CardioxaneClinigen GroupGlobalMergers & AcquisitionsNovartisOncologyPharmaceutical

Health care M&A spending falls nearly 40% in 2012, lowest year on record since 2003; report

22-01-2013

In 2012, dealmakers committed $143.3 billion to finance the year's activity in the health care merger,…

BiotechnologyGlobalMergers & AcquisitionsPharmaceutical

Investment in "pharmerging" markets at highest-ever level, according to Freshfields

02-01-2013

While global merger and acquisition (M&A) activity involving pharmaceutical companies has fallen to $146…

GlobalMergers & AcquisitionsPharmaceutical

Global generic drug markets will grow to $221 billion by 2016; Espicom

29-04-2012

The economic recession has been a double-edged sword for the international generic drugs business. Driven…

GenericsGlobalMarkets & MarketingMergers & AcquisitionsPricing

Global biotechnology market set to exceed $320 billion by 2015, says GIA

25-01-2012

The biotechnology industry was adversely affected by the global financial crisis, with several leading…

BiotechnologyGlobalMarkets & MarketingMergers & AcquisitionsResearch

Back to top